Back to search results

Germline Testing for Myeloid Malignancies

This study is looking at how well a new genetic test, called the MyeloGen Gene Panel, works for adults with myeloid malignancies (a type of blood cancer). The MyeloGen Gene Panel uses skin cells to check for genetic changes that might make someone more likely to get these cancers. The main goal is to see if this testing can be successfully completed. You might be able to join if you are 18 or older and have a myeloid malignancy or bone marrow failure. The study aims to enroll about 200 people, but its current recruitment status is unclear.

Study design
This is a single-arm study, meaning all participants receive the same intervention. About 200 people are expected to take part.
What's involved
You would have screening, in-clinic visits, fill out questionnaires, and have punch skin biopsies. The primary endpoint is measured at up to 10 weeks.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at up to 10 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07112287

Germline Testing for Predisposition to Myeloid Malignancies

Recruiting
NAAges 18+InterventionalScreening
Christopher Reilly
~200 participants
Updated 2026-04-24 on ClinicalTrials.gov
What's tested:MyeloGen Gene Panel

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Successful Completion Rate
Measured over Up to 10 weeks

Conditions

Myeloid Malignancy
Genetic Predisposition to Disease
Myeloid Hematological Malignancies

Explore related trials

Myeloid NeoplasmPancytopenia

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

  • Christopher R Reilly, MD · PRINCIPAL_INVESTIGATOR · Dana-Farber Cancer Institute

Who to contact

Christopher R Reilly, MD
[email protected]
407-443-6243
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age of 18 years or older
Participants must have histologically confirmed myeloid malignancy OR bone marrow failure within the last 6 months prior to screening.
Ability to understand and provide a signed and completed consent document in English.

Exclusion

Participants who cannot safely undergo clinically indicated skin biopsy as adjudicated by the study team.
Participants who have previously undergone germline genetic testing for predisposition to myeloid malignancies

What this trial measures

  • Successful Completion RateUp to 10 weeks

    Successful completion rate of germline genetic testing will be defined as the proportion of participants who return genetic test results within 10 weeks of study consent, which would require there be no excessive delays in obtaining a skin biopsy.